Pharmacological_JJ
control_NN
of_IN
antigen_NN
responsiveness_NN
in_IN
genetically_RB
modified_VBN
T_NN
lymphocytes_NNS
._.

A_DT
chimeric_JJ
TCR_NN
gene_NN
,_,
comprising_VBG
an_DT
anti-hapten_JJ
single-chain_JJ
Ab_NN
variable_JJ
fragment_NN
fused_VBN
to_TO
the_DT
transmembrane_NN
and_CC
cytoplasmic_JJ
regions_NNS
of_IN
the_DT
human_JJ
TCR_NN
zeta-chain_NN
,_,
was_VBD
used_VBN
to_TO
determine_VB
whether_IN
the_DT
tetracycline-regulatable_JJ
system_NN
could_MD
be_VB
used_VBN
to_TO
regulate_VB
gene_NN
expression_NN
in_IN
T_NN
cells_NNS
._.

Jurkat_NN
T_NN
cells_NNS
were_VBD
stably_RB
transfected_VBN
with_IN
a_DT
single_JJ
vector_NN
encoding_VBG
the_DT
tetracycline_NN
trans-activator_NN
protein_NN
,_,
controlled_VBN
by_IN
a_DT
constitutive_JJ
promoter_NN
,_,
and_CC
the_DT
chimeric_JJ
TCR_NN
,_,
under_IN
the_DT
control_NN
of_IN
a_DT
trans-activator_NN
protein-responsive_JJ
promoter_NN
._.

In_IN
the_DT
absence_NN
of_IN
tetracyclines_NNS
,_,
the_DT
transfected_VBN
T_NN
cells_NNS
were_VBD
shown_VBN
to_TO
express_VB
the_DT
chimeric_JJ
receptor_NN
on_IN
the_DT
cell_NN
surface_NN
and_CC
could_MD
be_VB
activated_VBN
by_IN
its_PRP$
cognate_JJ
Ag_NN
,_,
leading_VBG
to_TO
the_DT
secretion_NN
of_IN
IL-2_NN
._.

When_WRB
the_DT
cells_NNS
were_VBD
exposed_VBN
to_TO
increasing_VBG
concentrations_NNS
of_IN
tetracyclines_NNS
,_,
surface_NN
expression_NN
of_IN
the_DT
chimeric_JJ
receptor_NN
was_VBD
suppressed_VBN
in_IN
a_DT
dose-dependent_JJ
manner_NN
,_,
and_CC
this_DT
suppression_NN
was_VBD
sufficient_JJ
to_TO
result_VB
in_IN
complete_JJ
loss_NN
of_IN
responsiveness_NN
to_TO
the_DT
targeted_VBN
Ag_NN
._.

Prolonged_JJ
suppression_NN
of_IN
trans-gene_JJ
expression_NN
for_IN
up_RB
to_TO
7_CD
days_NNS
was_VBD
observed_VBN
after_IN
doxycycline_NN
was_VBD
removed_VBN
from_IN
the_DT
cultures_NNS
,_,
but_CC
eventual_JJ
recovery_NN
of_IN
surface_NN
expression_NN
was_VBD
complete_JJ
,_,
and_CC
the_DT
absolute_JJ
time_NN
to_TO
recovery_NN
was_VBD
directly_RB
proportional_JJ
to_TO
the_DT
initial_JJ
concentration_NN
of_IN
the_DT
drug_NN
._.

Pharmacologic_JJ
control_NN
of_IN
trans-gene_JJ
expression_NN
in_IN
gene-modified_JJ
T_NN
cells_NNS
will_MD
not_RB
only_RB
facilitate_VB
new_JJ
approaches_NNS
to_TO
the_DT
study_NN
of_IN
different_JJ
aspects_NNS
of_IN
T_NN
cell_NN
biology_NN
,_,
but_CC
will_MD
also_RB
provide_VB
the_DT
basis_NN
for_IN
new_JJ
gene_NN
therapy_NN
strategies_NNS
._.

